Do analysts recommend TELO or TVRD?

Tvardi Therapeutics has a consensus target price of $39.80, suggesting a potential upside of 1,593.62%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tvardi Therapeutics is more favorable than Telomir Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Tvardi Therapeutics 1 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.50

Is TELO or TVRD more profitable?

Tvardi Therapeutics' return on equity of -64.17% beat Telomir Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Telomir Pharmaceuticals N/A -201.23% -172.71% Tvardi Therapeutics N/A -64.17% -43.90%

Is RANI or TVRD more profitable?

Tvardi Therapeutics' return on equity of -64.17% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Rani Therapeutics N/A -206.46% -83.95% Tvardi Therapeutics N/A -64.17% -43.90%

Does the media prefer VRCA or TVRD?

In the previous week, Verrica Pharmaceuticals had 3 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 4 mentions for Verrica Pharmaceuticals and 1 mentions for Tvardi Therapeutics. Verrica Pharmaceuticals' average media sentiment score of 0.50 beat Tvardi Therapeutics' score of 0.00 indicating that Verrica Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verrica Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tvardi Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer TVRD or ETHZ?

Tvardi Therapeutics currently has a consensus price target of $39.80, suggesting a potential upside of 1,593.62%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Tvardi Therapeutics is more favorable than Flag Ship Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tvardi Therapeutics 1 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.50 Flag Ship Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is TVRD or ETHZ more profitable?

Tvardi Therapeutics' return on equity of -64.17% beat Flag Ship Acquisition's return on equity. Company Net Margins Return on Equity Return on Assets Tvardi Therapeutics N/A -64.17% -43.90% Flag Ship Acquisition N/A -185.71% -83.12%

Is TVRD or BDTX more profitable?

Black Diamond Therapeutics' return on equity of -30.18% beat Tvardi Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tvardi Therapeutics N/A -64.17% -43.90% Black Diamond Therapeutics N/A -30.18% -23.91%

Tvardi Therapeutics (TVRD) Competitors

$2.35 -0.07 (-2.89%)

Closing price 06/24/2026 04:00 PM Eastern

Extended Trading

$2.36 +0.01 (+0.43%)

As of 06/24/2026 05:44 PM Eastern

Compare

TVRD vs. TELO, RANI, VRCA, ETHZ, and BDTX

Should you buy Tvardi Therapeutics stock or one of its competitors? MarketBeat compares Tvardi Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tvardi Therapeutics include Telomir Pharmaceuticals (TELO), Rani Therapeutics (RANI), Verrica Pharmaceuticals (VRCA), Flag Ship Acquisition (ETHZ), and Black Diamond Therapeutics (BDTX). These companies are all part of the "pharmaceutical products" industry.

How does Tvardi Therapeutics compare to Telomir Pharmaceuticals?

Telomir Pharmaceuticals (NASDAQ:TELO) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

44.7% of Tvardi Therapeutics shares are owned by institutional investors. 7.4% of Tvardi Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Tvardi Therapeutics' return on equity of -64.17% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%
Tvardi Therapeutics	N/A	-64.17%	-43.90%

Telomir Pharmaceuticals has a beta of -0.24, meaning that its share price is 124% less volatile than the broader market. Comparatively, Tvardi Therapeutics has a beta of 0.33, meaning that its share price is 67% less volatile than the broader market.

Tvardi Therapeutics has a consensus target price of $39.80, suggesting a potential upside of 1,593.62%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tvardi Therapeutics is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tvardi Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50

Telomir Pharmaceuticals has higher earnings, but lower revenue than Tvardi Therapeutics. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Tvardi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A
Tvardi Therapeutics	$7.14M	3.09	-$18.21M	-$3.10	N/A

In the previous week, Tvardi Therapeutics had 1 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 1 mentions for Tvardi Therapeutics and 0 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 0.00 equaled Tvardi Therapeutics'average media sentiment score.

Company	Overall Sentiment
Telomir Pharmaceuticals	Neutral
Tvardi Therapeutics	Neutral

Summary

Tvardi Therapeutics beats Telomir Pharmaceuticals on 12 of the 14 factors compared between the two stocks.

How does Tvardi Therapeutics compare to Rani Therapeutics?

Rani Therapeutics (NASDAQ:RANI) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.

Rani Therapeutics presently has a consensus target price of $8.75, suggesting a potential upside of 1,040.81%. Tvardi Therapeutics has a consensus target price of $39.80, suggesting a potential upside of 1,593.62%. Given Tvardi Therapeutics' higher possible upside, analysts clearly believe Tvardi Therapeutics is more favorable than Rani Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Tvardi Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50

Tvardi Therapeutics' return on equity of -64.17% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rani Therapeutics	N/A	-206.46%	-83.95%
Tvardi Therapeutics	N/A	-64.17%	-43.90%

30.2% of Rani Therapeutics shares are held by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are held by institutional investors. 26.7% of Rani Therapeutics shares are held by insiders. Comparatively, 7.4% of Tvardi Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Tvardi Therapeutics has higher revenue and earnings than Rani Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than Tvardi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rani Therapeutics	$1.63M	58.29	-$29.67M	-$0.41	N/A
Tvardi Therapeutics	$7.14M	3.09	-$18.21M	-$3.10	N/A

In the previous week, Tvardi Therapeutics had 1 more articles in the media than Rani Therapeutics. MarketBeat recorded 1 mentions for Tvardi Therapeutics and 0 mentions for Rani Therapeutics. Rani Therapeutics' average media sentiment score of 0.00 equaled Tvardi Therapeutics'average media sentiment score.

Company	Overall Sentiment
Rani Therapeutics	Neutral
Tvardi Therapeutics	Neutral

Rani Therapeutics has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market. Comparatively, Tvardi Therapeutics has a beta of 0.33, indicating that its stock price is 67% less volatile than the broader market.

Summary

Tvardi Therapeutics beats Rani Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Tvardi Therapeutics compare to Verrica Pharmaceuticals?

Verrica Pharmaceuticals (NASDAQ:VRCA) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

Verrica Pharmaceuticals presently has a consensus target price of $14.50, suggesting a potential upside of 147.86%. Tvardi Therapeutics has a consensus target price of $39.80, suggesting a potential upside of 1,593.62%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tvardi Therapeutics is more favorable than Verrica Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Tvardi Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50

Verrica Pharmaceuticals has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market. Comparatively, Tvardi Therapeutics has a beta of 0.33, meaning that its stock price is 67% less volatile than the broader market.

Tvardi Therapeutics has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -47.97%. Tvardi Therapeutics' return on equity of -64.17% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%
Tvardi Therapeutics	N/A	-64.17%	-43.90%

Verrica Pharmaceuticals has higher revenue and earnings than Tvardi Therapeutics. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Tvardi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$35.58M	2.82	-$17.89M	-$1.03	N/A
Tvardi Therapeutics	$7.14M	3.09	-$18.21M	-$3.10	N/A

In the previous week, Verrica Pharmaceuticals had 3 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 4 mentions for Verrica Pharmaceuticals and 1 mentions for Tvardi Therapeutics. Verrica Pharmaceuticals' average media sentiment score of 0.50 beat Tvardi Therapeutics' score of 0.00 indicating that Verrica Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verrica Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tvardi Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

42.5% of Verrica Pharmaceuticals shares are held by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are held by institutional investors. 54.0% of Verrica Pharmaceuticals shares are held by company insiders. Comparatively, 7.4% of Tvardi Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Tvardi Therapeutics beats Verrica Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Tvardi Therapeutics compare to Flag Ship Acquisition?

Tvardi Therapeutics (NASDAQ:TVRD) and Flag Ship Acquisition (NASDAQ:ETHZ) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

In the previous week, Tvardi Therapeutics had 1 more articles in the media than Flag Ship Acquisition. MarketBeat recorded 1 mentions for Tvardi Therapeutics and 0 mentions for Flag Ship Acquisition. Tvardi Therapeutics' average media sentiment score of 0.00 equaled Flag Ship Acquisition'saverage media sentiment score.

Company	Overall Sentiment
Tvardi Therapeutics	Neutral
Flag Ship Acquisition	Neutral

Tvardi Therapeutics has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market. Comparatively, Flag Ship Acquisition has a beta of 1.17, indicating that its share price is 17% more volatile than the broader market.

Flag Ship Acquisition has lower revenue, but higher earnings than Tvardi Therapeutics. Tvardi Therapeutics is trading at a lower price-to-earnings ratio than Flag Ship Acquisition, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tvardi Therapeutics	$7.14M	3.09	-$18.21M	-$3.10	N/A
Flag Ship Acquisition	$4.11M	23.27	-$6.17M	-$159.65	N/A

44.7% of Tvardi Therapeutics shares are held by institutional investors. Comparatively, 4.1% of Flag Ship Acquisition shares are held by institutional investors. 7.4% of Tvardi Therapeutics shares are held by company insiders. Comparatively, 15.1% of Flag Ship Acquisition shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Tvardi Therapeutics currently has a consensus price target of $39.80, suggesting a potential upside of 1,593.62%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Tvardi Therapeutics is more favorable than Flag Ship Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tvardi Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50
Flag Ship Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Tvardi Therapeutics' return on equity of -64.17% beat Flag Ship Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tvardi Therapeutics	N/A	-64.17%	-43.90%
Flag Ship Acquisition	N/A	-185.71%	-83.12%

Summary

Tvardi Therapeutics beats Flag Ship Acquisition on 10 of the 15 factors compared between the two stocks.

How does Tvardi Therapeutics compare to Black Diamond Therapeutics?

Tvardi Therapeutics (NASDAQ:TVRD) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

Black Diamond Therapeutics' return on equity of -30.18% beat Tvardi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tvardi Therapeutics	N/A	-64.17%	-43.90%
Black Diamond Therapeutics	N/A	-30.18%	-23.91%

44.7% of Tvardi Therapeutics shares are held by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are held by institutional investors. 7.4% of Tvardi Therapeutics shares are held by company insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Tvardi Therapeutics has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market. Comparatively, Black Diamond Therapeutics has a beta of 3.22, indicating that its share price is 222% more volatile than the broader market.

In the previous week, Tvardi Therapeutics had 1 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 1 mentions for Tvardi Therapeutics and 0 mentions for Black Diamond Therapeutics. Tvardi Therapeutics' average media sentiment score of 0.00 equaled Black Diamond Therapeutics'average media sentiment score.

Company	Overall Sentiment
Tvardi Therapeutics	Neutral
Black Diamond Therapeutics	Neutral

Black Diamond Therapeutics has higher revenue and earnings than Tvardi Therapeutics. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Tvardi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tvardi Therapeutics	$7.14M	3.09	-$18.21M	-$3.10	N/A
Black Diamond Therapeutics	$70M	1.52	$22.37M	-$0.77	N/A

Tvardi Therapeutics currently has a consensus price target of $39.80, suggesting a potential upside of 1,593.62%. Black Diamond Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 437.63%. Given Tvardi Therapeutics' higher probable upside, equities analysts clearly believe Tvardi Therapeutics is more favorable than Black Diamond Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tvardi Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73

Summary

Black Diamond Therapeutics beats Tvardi Therapeutics on 10 of the 14 factors compared between the two stocks.

Get Tvardi Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TVRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TVRD vs. The Competition

Export

Metric	Tvardi Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$22.70M	$3.49B	$6.74B	$12.32B
Dividend Yield	N/A	2.28%	2.68%	5.88%
P/E Ratio	-0.76	20.50	25.39	23.96
Price / Sales	3.09	328.65	530.17	107.90
Price / Cash	N/A	130.96	45.29	53.76
Price / Book	1.05	8.26	10.76	6.41
Net Income	-$18.21M	$23.91M	$3.56B	$337.14M
7 Day Performance	-10.65%	2.12%	0.98%	-1.06%
1 Month Performance	-34.17%	2.40%	0.78%	0.49%
1 Year Performance	-91.33%	57.09%	30.24%	28.43%

Tvardi Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TVRD Tvardi Therapeutics	2.1255 of 5 stars	$2.35 -2.9%	$39.80 +1,593.6%	-91.8%	$22.70M	$7.14M	N/A	80
TELO Telomir Pharmaceuticals	0.4833 of 5 stars	$1.42 flat	N/A	-30.1%	$97.66M	N/A	N/A	1	High Trading Volume
RANI Rani Therapeutics	2.4259 of 5 stars	$0.78 flat	$8.75 +1,018.4%	+54.4%	$96.93M	$1.63M	N/A	110	Gap Up
VRCA Verrica Pharmaceuticals	3.1333 of 5 stars	$5.63 flat	$14.50 +157.5%	-2.2%	$96.72M	$35.58M	N/A	40	News Coverage
ETHZ Flag Ship Acquisition	N/A	$5.05 -0.6%	N/A	N/A	$96.01M	$4.11M	N/A	7

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TVRD) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tvardi Therapeutics (TVRD) Competitors

TVRD vs. TELO, RANI, VRCA, ETHZ, and BDTX

How does Tvardi Therapeutics compare to Telomir Pharmaceuticals?

Summary

How does Tvardi Therapeutics compare to Rani Therapeutics?

Summary

How does Tvardi Therapeutics compare to Verrica Pharmaceuticals?

Summary

How does Tvardi Therapeutics compare to Flag Ship Acquisition?

Summary

How does Tvardi Therapeutics compare to Black Diamond Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVRD vs. The Competition

Tvardi Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tvardi Therapeutics (TVRD) Competitors

TVRD vs. TELO, RANI, VRCA, ETHZ, and BDTX

How does Tvardi Therapeutics compare to Telomir Pharmaceuticals?

Do insiders & institutionals hold more shares of TELO or TVRD?

Is TELO or TVRD more profitable?

Which has more volatility and risk, TELO or TVRD?

Do analysts recommend TELO or TVRD?

Which has stronger earnings & valuation, TELO or TVRD?

Does the media favor TELO or TVRD?

Summary

How does Tvardi Therapeutics compare to Rani Therapeutics?

Do analysts prefer RANI or TVRD?

Is RANI or TVRD more profitable?

Do institutionals & insiders hold more shares of RANI or TVRD?

Which has preferable earnings and valuation, RANI or TVRD?

Does the media refer more to RANI or TVRD?

Which has more risk and volatility, RANI or TVRD?

Summary

How does Tvardi Therapeutics compare to Verrica Pharmaceuticals?

Do analysts recommend VRCA or TVRD?

Which has more volatility & risk, VRCA or TVRD?

Is VRCA or TVRD more profitable?

Which has preferable earnings and valuation, VRCA or TVRD?

Does the media prefer VRCA or TVRD?

Do institutionals and insiders have more ownership in VRCA or TVRD?

Summary

How does Tvardi Therapeutics compare to Flag Ship Acquisition?

Does the media refer more to TVRD or ETHZ?

Which has more volatility and risk, TVRD or ETHZ?

Which has preferable valuation and earnings, TVRD or ETHZ?

Do insiders and institutionals hold more shares of TVRD or ETHZ?

Do analysts prefer TVRD or ETHZ?

Is TVRD or ETHZ more profitable?

Summary

How does Tvardi Therapeutics compare to Black Diamond Therapeutics?

Is TVRD or BDTX more profitable?

Do insiders and institutionals hold more shares of TVRD or BDTX?

Which has more volatility and risk, TVRD or BDTX?

Does the media refer more to TVRD or BDTX?

Which has preferable valuation and earnings, TVRD or BDTX?

Do analysts prefer TVRD or BDTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVRD vs. The Competition

Tvardi Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools